Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.

ABSTRACT:

Objective

To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors in routine clinical practice.

Design

Cohort study using data from nationwide registers and an active-comparator new-user design.

Setting

Denmark, Norway, and Sweden, from April 2013 to December 2016.

Participants

20 983 new users of SGLT2 inhibitors and 20 983 new users of dipeptidyl peptidase 4 (DPP4) inhibitors, aged 35-84, matched by age, sex, history of major cardiovascular disease, and propensity score.

Main outcome measures

Primary outcomes were major cardiovascular events (composite of myocardial infarction, stroke, and cardiovascular death) and heart failure (hospital admission for heart failure or death due to heart failure). Secondary

SUBMITTER: Pasternak B 

PROVIDER: S-EPMC6713906 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature